# Fulcrum Therapeutics, Inc. (FULC): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Fulcrum Therapeutics, Inc. (FULC) is 12/100, ranked against 24,000+ stocks in 35 markets (Quality 32, Value 34, Momentum 21, each scored against its sector).

- StockRank: 12/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 32, Value 34, Momentum 21: each a 0-100 percentile within Healthcare.
- Position: #23,323 overall, #2,209 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 3.64 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 66K; 5%+ holders bought USD 1.5M.

Source: https://moatmap.ai/stock/FULC
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker